This inventor holds 2 USPTO granted patents, plus 2 CIPO patents and 2 EPO patents. Top assignee: Kedrion S.p.a.. Active years: 2014-2015.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2014-2015
Title: Pierangelo Giovacchini: Innovator in Pharmaceutical Compositions
Introduction
Pierangelo Giovacchini is a notable inventor based in Lammari-Capannori, Italy. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment and prevention of autoimmune diseases. With a total of 2 patents to his name, his work reflects a commitment to advancing medical science.
Latest Patents
Giovacchini's latest patents include innovative pharmaceutical compositions that utilize transferrin for the treatment and/or prophylaxis of autoimmune diseases. This invention describes how APOTf can modify the immune response profile favorably, both in vitro and in vivo. Another significant patent involves a process for preparing a virus-inactivated FV concentrate from human plasma. This process is designed to be simple, scalable to an industrial level, and cost-effective compared to existing methods. It incorporates two anion exchange chromatography steps, ensuring the safety and stability of the final product.
Career Highlights
Pierangelo Giovacchini is associated with Kedrion S.p.a., a company known for its focus on biopharmaceuticals. His work at Kedrion has allowed him to explore and develop innovative solutions in the field of immunology and plasma-derived therapies.
Collaborations
Giovacchini has collaborated with notable colleagues such as Claudio Farina and Ester Ascione. These partnerships have contributed to the advancement of his research and the successful development of his patents.
Conclusion
Pierangelo Giovacchini's contributions to pharmaceutical innovations demonstrate his expertise and dedication to improving healthcare solutions. His patents reflect a significant impact on the treatment of autoimmune diseases and the purification of vital proteins.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile